Entrada Therapeutics, Inc. Income Statement
TRDA|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Entrada Therapeutics, Inc. reported $211M in revenue and $66M in net income for FY2025. Revenue has grown at a 27.8% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $210.8M | $129.0M | $129.0M |
| SG&A Expense | $38.5M | $32.3M | $30.6M |
| R&D Expense | $125.3M | $99.9M | $66.6M |
| Operating Income | $47.0M | -$3.2M | -$97.2M |
| Income Tax | $859.0K | $18.7M | $0 |
| Net Income | $65.6M | -$6.7M | -$94.6M |
| EPS (Basic) | $1.76 | -$0.20 | -$3.02 |
| EPS (Diluted) | $1.68 | -$0.20 | -$3.02 |
| Shares Outstanding | 37.6M | 33.4M | 31.4M |
| Operating Margin | 22.3% | -2.5% | -75.4% |
| Profit Margin | 31.1% | -5.2% | -73.3% |